This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Walgreens Closes PharMerica Buyout as KKR's Minority Partner
by Zacks Equity Research
Walgreens (WBA) along with privately-held global investment firm KKR completes the acquisition of Pharmerica for $1.4 billion. The merger agreement was announced in August.
Genomic Health at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.
Here's Why You Should Bet on WESCO International (WCC) Stock
by Zacks Equity Research
WESCO International, Inc. (WCC) continues to perform well, driven by differentiated products, strength across all end markets, improved execution and positive pricing.
Myriad Genetics Presents Favorable EMBRACA Trial Results
by Zacks Equity Research
Myriad Genetics (MYGN) adopts initiatives to boost uptake of BRACAnalysis CDx test.
Wright Medical (WMGI) Acquires IMASCAP SAS for $88.8 Million
by Zacks Equity Research
Wright Medical's (WMGI) acquisition of IMASCAP SAS will strengthen Extremities business.
Adobe (ADBE) Beats on Q4 Earnings, Issues Guidance for 2018
by Zacks Equity Research
Adobe Systems Inc. (ADBE) reports strong fiscal fourth-quarter results, driven by robust growth in its cloud-based subscription products.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) banks on product launches and international market prospects.
Myriad Genetics Rides on Solid Molecular Diagnostics Suite
by Zacks Equity Research
Myriad Genetics (MYGN) adopts initiatives to boost the Molecular Diagnostics portfolio.
CVS Health Banks on Solid Pharmacy Services, Competition Rife
by Zacks Equity Research
CVS Health's (CVS) strong 2018 PBM selling season buoys optimism.
6 Reasons to Invest in Beacon Roofing (BECN) Stock Right Now
by Zacks Equity Research
Beacon Roofing Supply (BECN) is witnessing strong sales growth within each of its three product lines and geographies. This is projected to continue in fiscal 2018 as well.
NuVasive (NUVA) to Acquire SafePassage, Strengthens IONM
by Zacks Equity Research
NuVasive's (NUVA) combined entity with SafePassage seems strategic as the move will fortify the NuVasive Clinical Services' (NCS) status as the largest U.S. provider of outsourced IONM services.
Top Ranked Growth Stocks to Buy for December 14th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 14th:
Wayfair to Add 3 Distribution Centers, 100 Jobs in Florida
by Zacks Equity Research
Wayfair Inc. (W) intends to open three new fulfillment centers in Florida in order to expand its operations and ensure faster delivery of goods to its customers.
Top Ranked Growth Stocks to Buy for December 13th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 13th:
Boston Scientific Receives FDA Nod for Vercise DBS System
by Zacks Equity Research
Boston Scientific (BSX) forges ahead with initiatives to boost DBS portfolio under Neuromodulation business.
Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm
by Zacks Equity Research
Smith & Nephew's (SNN) completion of Rotation Medical acquisition appears highly strategic as this will consolidate the company's position in disruptive technologies and advance its overall growth.
Hill-Rom (HRC) Banks on Strategic Buyouts, Competition Rife
by Zacks Equity Research
Hill-Rom's (HRC) upbeat long-term view buoys optimism.
Omnicell's Rising Costs Affect Bottom Line Amid Competition
by Zacks Equity Research
Soft margin scenario is a headwind for Omnicell (OMCL). The company's strategic endeavors such as portfolio expansion, acquisitions and new market growth persistently escalate expenses.
Amazon's Music Service and Echo Available in 28 New Markets
by Zacks Equity Research
Amazon (AMZN) launches its Music streaming service and Echo devices in 28 countries.
Myriad Genetics Presents Encouraging EndoPredict Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) forges ahead with initiatives to boost the Molecular Diagnostics portfolio.
Cooper Companies (COO) Tops Q4 Earnings & Revenue Estimates
by Zacks Equity Research
Cooper Companies (COO) continues to witness impressive results at the CooperVision business segment that delivered strong sales in Q4.
Top Ranked Growth Stocks to Buy for December 11th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 11th:
Varian Halcyon Gets ANVISA Registration, Grows in Oncology
by Zacks Equity Research
Varian (VAR) consistently tries to expand in the global market with Halcyon system.
Myriad Genetics (MYGN) Presents Positive riskScore Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) presents positive riskScore data at the SABCS. With riskScore, the company intends to boost its myRisk Hereditary Cancer test suite.
Maxim (MXIM) Inks Catalog Distribution Deal With CoreStaff
by Zacks Equity Research
Maxim Integrated Products (MXIM) inked a catalog distribution agreement with CoreStaff Co., Ltd. The deal will give Maxim a vast distribution network and expand its geographical presence.